Gracell Biotechnologies Announces China Nmpa Clearance For Ind Application For Phase 1/2 Clinical Trial Of Fastcar-T Gc012F For Treatment Of Relapsed/Refractory Multiple Myeloma

Approval Follows U.S. Fda Clearance Of Ind Application For Bcma/Cd19 Dual-Targeting Fastcar-T Gc012FCompany Plans To Initiate Phase 1/2 Clinical Trial In China In Third Quarter Of 2023Gracell Biotechnologies Inc A Global Clinical-Stage Biopharmaceutical Company Dedicated To Developing Highly Efficacious And Affordable Cell Therapies For The Treatment Of Cancer, Today Announced That The Center For Drug Evaluation (Cde) Of China'S National Medical Products Administration (Nmpa) Has Cleared Gracell'S Investigational New Drug (Ind) Application For Gc012F, An Autologous Car-T Therapeutic Candidate, For The Treatment Of Relapsed/Refractory Multiple Myeloma (Rrmm).Gracell Plans To Initiate A Phase 1/2, Single-Arm, Open-Label, Multi-Center Trial In China In The Third Quarter Of 2023 To Further Evaluate Gc012F In Rrmm Patients. Following The U.S. Fda'S Clearance Of Gracell'S Ind Application Announced On Feb. 3, Gracell Also Plans To Initiate A Phase 1B/2 Clinical Trial In The U.S. In The Second Quarter Of 2023.Gc012F Is An Autologous Car-T Therapeutic Candidate Dual-Targeting B Cell Maturation Antigen (Bcma) And Cd19, And Utilizes Gracell'S Proprietary Fastcar Next-Day Manufacturing Platform. In November 2021, The Fda Granted Gc012F Orphan Drug Designation For The Treatment Of Multiple Myeloma. Gc012F Is Currently Being Studied In Multiple Investigator-Initiated Trials (Iit) Evaluating Its Safety And Efficacy In Rrmm, Newly-Diagnosed Multiple Myeloma, And B-Cell Non-Hodgkin'S Lymphoma (B-Nhl). At The European Hematology Association 2022 Hybrid Congress, Gracell Presented Longer-Term Follow-Up Clinical Data Of Gc012F In Rrmm That Showed A 100% Minimal Residual Disease (Mrd) Negativity Rate In All Patients Treated."This Milestone Marks Successful Regulatory Clearances To Commence Key Clinical Trials For Gracell'S Lead Asset, Gc012F, In Both China And The United States," Said Dr. William (Wei) Cao, Founder, Chairman, And Ceo Of Gracell. "We Believe Gc012F Has Vast Potential To Meaningfully Improve Cancer Care, Including The Faster Delivery To Patients Enabled By Gracell'S Fastcar Next-Day Manufacturing And A Novel Approach Of Bcma And Cd19 Dual-Targeting In Multiple Indications. Gracell Is Committed To Developing Innovative Cell Therapies To Transform Patients' Lives, And We Look Forward To Launching The Phase 1/2 Ind Trial In China To Further Study Gc012F." Gc012F Is A Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Product Candidate That Is Currently Being Evaluated In Iit Studies In China For The Treatment Of Multiple Myeloma And B-Cell Non-Hodgkin'S Lymphoma. Gc012F Simultaneously Targets Cd19 And Bcma To Drive Fast, Deep And Durable Responses, Which Can Potentially Improve Efficacy And Reduce Relapse In Multiple Myeloma And B-Nhl Patients Car-T Cells Manufactured On Gracell'S Proprietary Fastcar Platform Appear Younger, Less Exhausted And Show Enhanced Proliferation, Persistence, Bone Marrow Migration And Tumor Cell Clearance Activities As Demonstrated In Preclinical Studies. With Next-Day Manufacturing, Fastcar Is Able To Significantly Improve Cell Production Efficiency Which May Result In Meaningful Cost Savings, And, Together With Fast Release Time, Enables Enhanced Accessibility Of Cell Therapies For Cancer Patients Gracell Biotechnologies Inc. ("Gracell") Is A Global Clinical-Stage Biopharmaceutical Company Dedicated To Discovering And Developing Breakthrough Cell Therapies. Leveraging Its Pioneering Fastcar And Truucar Technology Platforms And Smart Carttm Technology Module, Gracell Is Developing A Rich Clinical-Stage Pipeline Of Multiple Autologous And Allogeneic Product Candidates With The Potential To Overcome Major Industry Challenges That Persist With Conventional Car-T Therapies, Including Lengthy Manufacturing Time, Suboptimal Cell Quality, High Therapy Cost And Lack Of Effective Car-T Therapies For Solid Tumors

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!